TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial fo… Read more
TWi Biotechnology, Inc. - Asset Resilience Ratio
TWi Biotechnology, Inc. (6610) has an Asset Resilience Ratio of 20.14% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how TWi Biotechnology, Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down TWi Biotechnology, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$48.80 Million | 20.14% |
| Total Liquid Assets | NT$48.80 Million | 20.14% |
Asset Resilience Insights
- Good Liquidity Position: TWi Biotechnology, Inc. maintains a healthy 20.14% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
TWi Biotechnology, Inc. Industry Peers by Asset Resilience Ratio
Compare TWi Biotechnology, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for TWi Biotechnology, Inc. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for TWi Biotechnology, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.14% | NT$48.80 Million | NT$242.32 Million | -23.17pp |
| 2023-12-31 | 43.30% | NT$171.85 Million | NT$396.85 Million | +32.28pp |
| 2021-12-31 | 11.03% | NT$34.30 Million | NT$311.04 Million | -27.26pp |
| 2020-12-31 | 38.29% | NT$148.20 Million | NT$387.04 Million | -38.38pp |
| 2019-12-31 | 76.68% | NT$329.02 Million | NT$429.10 Million | -- |